Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Endocrine cardiomyopathy: response to cyclic GMP PDE5 inhibition in acromegaly cardiomyopathy
2015-004498-34Phase 2Active
- Sponsor
- Azienda Ospedaliero-Universitaria Policlinico Umberto I
- Start
- Jan 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of tadalafil in Acromegalic cardiomyopathy (ACM) and acromegaly, sponsored by Azienda Ospedaliero-Universitaria Policlinico Umberto I. Primary endpoint: Change of left ventricular torsion. Started Jan 2018; status: active.
02
Drugs
tadalafil
03
Conditions
Acromegalic cardiomyopathy (ACM)acromegaly
Beyond the preview
Go deeper on 2015-004498-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-004498-34.